PTGX

Protagonist Therapeutics Inc

NASDAQ

Add Alert

PTGX

Protagonist Therapeutics Inc

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

Monksdream PremiumMember

03/03/24 9:42 AM

Post #69

PTGX new 52 week high

ErnieBilco PremiumMember

03/07/23 3:36 PM

Post #68

Looks like I left $3 early but made money so it okay. Can't get out at the top all the time.

ErnieBilco PremiumMember

03/07/23 1:08 PM

Post #67

Well I let mine go today @ $20

ziggy7796

04/27/22 7:13 AM

Post #66

Pulled from yahoo finance...this stock could explode 4x if phase 3 does well...cheers ziggy

?

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

April 25, 2022, 4:25 pm

PN-943 achieved 27.5% clinical remission with a delta of 13% versus placebo, with strong concordance across all key proxies including histological and endoscopic endpoints for efficacy, in the twice daily 150 mg dose arm
Achieved clinical proof-of-concept and validation for oral, gut-restricted approach for ulcerative colitis via blockade of the alpha-4-beta-7-integrin pathway
Plans underway for a registrational Phase 3 study anchored around twice daily 150 mg dose of PN-943, pending regulatory guidance

Protagonist to host a conference call today at 6:00 p.m. ET
NEWARK, Calif., April 25, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).
"We are delighted with the strength of the results from the IDEAL study and look forward to working with the regulatory agencies as we prepare for a Phase 3 registrational program for PN-943 in moderate-to-severe ulcerative colitis," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist. "Our oral, gut-restricted alpha-4-beta-7-integrin antagonist agent PN-943 has demonstrated clinical efficacy on par with the approved injectable antibody drug working through the same biological target. We believe the results of the IDEAL study may be paradigm shifting and of broad scientific relevance in understanding IBD pathogenesis and gut-restricted drug development via intervention of the integrin-MAdCAM pathway. Based on its convenience of oral administration and the favorable efficacy and safety results observed to date, we believe that PN-943 has the potential to become a first-in-class, foundational oral medicine for individuals living with moderate-to-severe ulcerative colitis."

"With the IDEAL study, we have demonstrated clinical proof-of-concept and validation for potential treatment of ulcerative colitis via oral, gut-restricted blockade of the alpha-4-beta-7-integrin pathway," said Scott Plevy, M.D., Executive Vice President and Therapeutic Head of Gastroenterology at Protagonist. "The study assessed two doses of PN-943, 150 mg BID and 450 mg BID, and demonstrated a very clear and consistent treatment effect at the lower 150 mg BID dose across key endpoints. The dose response demonstrated by this study is consistent with several other modalities in the integrin pathway. The findings in the lower-dose arm provide consistent evidence of clinical efficacy and safety, and clear direction on the dosing regimen for the Phase 3 registrational program."
"The oral, gut-restricted agent PN-943 appears to exert similar effects at the twice daily 150 mg dose in comparison to the approved injectable alpha-4-beta-7-integrin antibody drug and its mechanism of action," said Bruce Sands, M.D., M.S., the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, principal investigator for the IDEAL study and consultant to Protagonist. "There is a clear unmet need and strong clinical benefit for patients with an oral agent working through such a proven IBD specific mechanism, and the IDEAL study results provide good rationale for moving PN-943 forward in a Phase 3 registrational study."
Summary of Key Results
IDEAL is a randomized, double-blinded, placebo-controlled, multicenter Phase 2 study to evaluate the safety and efficacy of PN-943, an oral, gut-restricted, alpha-4-beta-7-integrin antagonist. 159 patients with moderate-to-severe active UC were randomized to either twice daily (BID) with 450 mg or 150 mg PN-943, or placebo, for 12 weeks and analyzed for outcome measures.
While the 450 mg BID dose did not meet the prespecified primary endpoint, the 150 mg dose achieved a placebo versus treatment delta of 13% (p=0.08) in the modified Intent to Treat (mITT) group, and a delta of 16% (p=0.04) in the bio-naïve group. In addition, the 150 mg BID data showed strong concordance across multiple parameters including statistically significant histological remission and endoscopic improvement.
PN-943 150 mg BID dose forms the basis for a Phase 3 registrational program

27.5% clinical remission vs 14.5% in placebo (delta 13%, p=0.08) for mITT analysis

Strong concordance with efficacy across multiple key secondary endpoints with statistically significant differences in histologic remission/improvement and endoscopic improvement

Safety analysis similar for the 150 mg BID dose versus the placebo group

ziggy7796

04/26/22 11:13 AM

Post #65

Just...pulled this...ziggy.

Protagonist Therapeutics: Biotechnology company Protagonist Therapeutics (NASDAQ:PTGX) remains on the Fintel short squeeze leaderboard at the same position it held last week. Fintel shows 12.8% of the float short and a borrow fee rate of 16.88. Short interest is climbing in the company’s shares, according to the report.

ziggy7796

04/26/22 11:02 AM

Post #64

Re: #63: @ziggy7796 - Also....2.5 million shares traded is low for a

Trading volume picking up...let's see what happens.

ziggy7796

04/26/22 10:47 AM

Post #63

Also....2.5 million shares traded is low for a 48 million market cap....

I smell shorts in the water right now!!!

ziggy7796

04/26/22 10:44 AM

Post #62

Re: #61: @ErnieBilco - I'm bewildered because their Ph2 results were very

Watch what happens in the next 4 hrs.....I truly think it was an aggressive short attack....a week ago...this was trading at $25....as of 10:30am today...$12.???????...a billion market cap company ...with $27 million rev and some analysts looking at $50 rating does not implode this quickly.....remember...they are going forward with 150mg dosage in their new drug via phase III.....but reevaluating the 450mg dosage that did not perform well..

..I think novice investors just panicked and dump when shorter attacked last night and they only read the negative test results... you have to have a set of stones to hold on right now....but a 4x return on my $12 price would be nice return for me.

Remember what Warren buffet say...".when investors are fearful...buy!!!"

Good luck...... cheers ziggy

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Protagonist Therapeutics (PTGX – Research Report), Gossamer Bio (GOSS – Research Report) and Black Diamond Therapeutics (BDTX – Research Report).
Protagonist Therapeutics (PTGX)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $50.00. The company’s shares closed last Monday at $18.80, close to its 52-week low of $12.80.
According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.2% and a 40.4% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.
Protagonist Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $49.20, implying a 163.0% upside from current levels. In a report issued on April 11, BTIG also maintained a Buy rating on the stock with a $55.00 price target.
See Insiders’ Hot Stocks on TipRanks >>

ErnieBilco PremiumMember

04/26/22 10:30 AM

Post #61

Re: #60: @ziggy7796 - Not sure....I thought buying back at 12 was

I'm bewildered because their Ph2 results were very good from my reading of it - prepping for Ph3 on their UC candidate.

Analyst maintains a $50 price target

It's gotta be a short attack unless someone else can find more info on the drop.

ziggy7796

04/26/22 10:24 AM

Post #60

Re: #59: @ErnieBilco - OMG, what a massacre - Is it a

Not sure....I thought buying back at 12 was a good bottom .... but see if you can bring some light to the avalanche! Ziggy

ErnieBilco PremiumMember

04/26/22 10:01 AM

Post #59

OMG, what a massacre - Is it a short attack or is there something wrong with the company?

ziggy7796

04/18/22 10:25 AM

Post #58

This has potential to rebound nicely after Thursdays dip of 25%.

north40000 PremiumMember

04/13/22 7:31 PM

Post #57

Re: #56: @ErnieBilco - That would do it - thanks

I sold 500 shares. See Dew @ Bio Tech Value after hours.

ErnieBilco PremiumMember

04/13/22 7:28 PM

Post #56

Re: #55: @north40000 - FDA revoked break-through therapy designation for one of

That would do it - thanks

north40000 PremiumMember

04/13/22 7:26 PM

Post #55

Re: #54: @ErnieBilco - Just bought back in after a long hiatis

FDA revoked break-through therapy designation for one of its meds. No PR yet from PTGX after hours.

ErnieBilco PremiumMember

04/13/22 6:12 PM

Post #54

Just bought back in after a long hiatis - gotta see if I can bank like the last time

ok2buy

11/10/21 10:03 AM

Post #53

Continued movement upward in advance of conference. More exposure, this will help to profile the company and what they are trying to accomplish./ok2

ok2buy

11/05/21 9:11 AM

Post #52

Great news yesterday. Company will be presenting 2 abstracts on rusfertide at the American Society of Hematology (ASH) meeting on Dec. 11 - 15/21. Looking strong this morning in premarket. Best of luck to the longs./

ok2buy

10/13/21 10:09 AM

Post #51

Open down, then up, now back down again. Still think there is money to be made on this one. I reduced my position on the run up, but still holding some in the event there is a jump again./ok2

rib eye

10/12/21 4:42 PM

Post #50

Re: #49: @ok2buy - Had hoped that this would continue to move

I agree. pullback was to be expected. Suoport is just under $30. likely to be tested AH

ok2buy

10/12/21 4:32 PM

Post #49

Re: #48: @rib eye - Volume has tapered off, but still getting ugly.

Had hoped that this would continue to move back up. But I believe with the huge run the stock had yesterday, a healthy pull back is fine. We'll see what tomorrow brings. Lots of buying yesterday and many who bought would be out of the money after 24 hours. I still think this moves higher. Best of luck to the longs./ok2

rib eye

10/12/21 1:15 PM

Post #48

Re: #47: @ok2buy - Buckle up. Believe this will move back up./ok2

Volume has tapered off, but still getting ugly. Heading under $30.

ok2buy

10/12/21 9:51 AM

Post #47

Buckle up. Believe this will move back up./ok2

ok2buy

10/12/21 9:47 AM

Post #46

Shake the tree now. Institutions looking to grab some cheapies?/ok2

ok2buy

10/12/21 9:29 AM

Post #45

A couple new price targets posted minutes ago, SVB Leerink from $35 to $50 and JP Morgan to $55.00. All the best./ok2

conix

10/11/21 5:07 PM

Post #44

Re: #43: @crudeoil24 - 36.55

PTGX Chart

crudeoil24 PremiumMember

10/11/21 12:47 PM

Post #43

36.55

ErnieBilco PremiumMember

10/11/21 11:05 AM

Post #42

Out at $35

ok2buy

10/11/21 9:49 AM

Post #41

Buckle up. I believe we retest this morning's high./ok2

ok2buy

10/11/21 9:29 AM

Post #40

The FDA lifted the hold, this could easily move back to $40.00/share or higher. Hit $35.00 + in premarket trading. Best of luck to the retailers./ok2

ok2buy

10/08/21 10:17 AM

Post #39

Setting up to break through $20.00./ok2

dealerschool2006 Free

10/07/21 11:04 AM

Post #38

Re: #37: @Peach_Tree - Any thoughts on where this is going to go?

I'm not the on to ask about PTGX, sorry...

Peach_Tree Free

10/07/21 10:34 AM

Post #37

Re: #35: @dealerschool2006 - I like to scan for panic sales like

Any thoughts on where this is going to go?

ok2buy

10/07/21 10:34 AM

Post #36

Company asked to present at the AASLD "Liver Meeting". Hoping that goes well and provides some positive exposure. Remember, if you are fortunate to own some shares, this one is mostly held by large institutions. In my opinion, buy on weakness, still expecting good things with this one. Here is the link./ok2

https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-data-from-phase-2-rusfertide-study-in-hereditary-hemochromatosis-selected-for-oral-presentation-at-the-annual-aasld-meeting-301391354.html

dealerschool2006 Free

09/27/21 2:18 PM

Post #35

Re: #34: @ok2buy - For investors, the following information:

I like to scan for panic sales like PTGX and try to buy the dips, but I'm outa powder now...I had one last year and the next day it popped 400% AND kept on going for awhile...itsa good buy in the dipping cycle when Institutions load up...

ok2buy

09/25/21 12:21 PM

Post #34

For investors, the following information:
From Refinitiv stock reports (Sept.24/21), they quote amongst 8 analysts polled, a 12 month price target, Low - $18.00, High - $93.00, with a Mean - $44.30.

JMP Securities (Sept. 22/21) reduced their target from $55.00 to $47.00.

From Morningstar (Sept. 24/21), PTGX is reported to be held at a level of 100 % by Institutional investors.

If you are a retail investor and are lucky enough to have grabbed some shares, in my opinion it may be wise to hold. Please do your own dd!

If we look at Friday's close @ $18.81 and compare that to the Refinitv Mean price target, you are looking at an increase of $44.30/$18.81 = 235.5 %.

The current 52 week high that is listed for the stock is $50.54, that would be an increase on Fridays' close, $50.54/$18.81 = 268.7 %.

Finally, pie in the sky, the high end of analyst estimates is $93.00/share, that would be an increase on Friday's close, $93.00/$18.81 = 494.4 %.

As always, please do your own due diligence. My personal opinion, is that there is still $$ to be made on this one! Good luck to all investors, but especially the retail investors. And remember, Institutional investors don't like to lose their money! Best of luck./ok2

ok2buy

09/23/21 9:43 AM

Post #33

Just watched a large order get filled @ $16.00/share. This was no retail buy! Institutions are loading up again. Stock moving back up. With favorable news, could easily retest highs. IMO. Best of luck to the longs./ok2

ok2buy

09/23/21 8:44 AM

Post #32

The company is cooperating with the FDA. Nothing but transparency here. Once resolved I see a rapid movement back above $20 and then higher. Retailers, hold your shares. Some patience required here. Smart money has accumulated on the dip. Institutions have a large presence here. They don't want to lose their money. IMO. Best of luck to the longs./ok2

dealerschool2006 Free

09/17/21 4:15 PM

Post #31

Re: #30: @YazM - Will be buying about 5000 shares here before

what a dip for PTGX...back to the drawing board...

YazM

09/17/21 1:27 PM

Post #30

Re: #29: @ErnieBilco - Bought a small starter for an eventual bounce back.

Will be buying about 5000 shares here before the EOD. I see this being in the green at least 5-10% easy on Monday. Massive consolidation here at the $17 PPS.

ErnieBilco PremiumMember

09/17/21 11:17 AM

Post #29

Bought a small starter for an eventual bounce back.

ClayTrader Free

05/08/20 5:56 PM

Post #28

* * $PTGX Video Chart 05-08-2020 * *

Link to Video - click here to watch the technical chart video

keekee

12/05/19 11:25 AM

Post #27

Re: #25: @europtiger - Imo this goes a bid more then 9

Add at $7.44. And I know the idiots I brought it from. Just cracking up at their last effort to breathe before their killing
LMFAOO

ClayTrader Free

12/04/19 4:52 PM

Post #26

* * $PTGX Video Chart 12-04-2019 * *

Link to Video - click here to watch the technical chart video

europtiger Free

12/04/19 1:58 PM

Post #25

Re: #24: @keekee - With se some.T $9 and the others

Imo this goes a bid more then 9

keekee

12/04/19 1:36 PM

Post #24

Re: #21: @keekee - $9 _$10 now. Likely today too

With se some.T $9 and the others to $10...guaranteed by tomorrow

keekee

12/04/19 1:35 PM

Post #23

Re: #21: @keekee - $9 _$10 now. Likely today too

Almost there....money in the bank now at $9. Cheers

keekee

12/04/19 12:31 PM

Post #22

Re: #20: @BoilerRoom - Strong swings

Lol...idiots trying to stop a moving train. I am cracking up hard here...$9_$10!!!!!!

keekee

12/04/19 12:11 PM

Post #21

Re: #20: @BoilerRoom - Strong swings

$9 _$10 now. Likely today too

BoilerRoom Free

12/04/19 11:25 AM

Post #20

Re: #19: @TheFinalCD - this is crazy, crashed to 4.47 on bad

Strong swings

Older

Protagonist Therapeutics Inc (PTGX)

Followers	5	Posters	23
Posts (Today)	0	Posts (Total)	69
Created	08/25/16	Type	Free
Moderators

Protagonist Therapeutics, Inc. (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist's primary focus is on developing oral peptide drugs that specifically target biological pathways. Its oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment. The Company's initial lead product candidates, PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease (IBD), a GI disease consisting primarily of ulcerative colitis (UC) and Crohn's disease (CD). Protagonist's product candidate beyond IBD is PTG-300, which is an injectable hepcidin mimetic peptide that the Company is developing for the treatment of iron overload disorders, such as transfusion-dependent b-Thalassemia, hereditary hemochromatosis (HH) and sickle cell disease (SCD).